1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Product Pipeline Analysis
3.9. Incidence and Prevalence Analysis
3.10. Patent Analysis
4. TECHNOLOGICAL OUTLOOK
5. ADVANCED MEDICAL IMAGING DIAGNOSTICS MARKET BY PRODUCT TYPE
5.1. Introduction
5.2 Magnetic Resonance Imaging (MRI)
5.3. Computed Tomography (CT)
5.4. X-ray Imaging
5.5. Ultrasound Imaging
5.6. Positron Emission Tomography (PET)
6. ADVANCED MEDICAL IMAGING DIAGNOSTICS MARKET BY PRODUCT TYPE
6.1. Introduction
6.2. Imaging Systems
6.3. Software Solutions
6.4. Services
7. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET BY APPLICATION
7.1. Introduction
7.2. Oncology
7.3. Cardiology
7.4. Neurology
7.5. Orthopedics
7.6. Gastroenterology
8. ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Siemens Healthineers
10.2. GE HealthCare
10.3. Philips Healthcare
10.4. Canon Medical Systems
10.5. Fujifilm Healthcare
10.6. Hologic
10.7. Carestream Health
10.8. Hitachi Healthcare
10.9. Agfa-Gevaert Group
10.10. Shimadzu Corporation
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations